Roy C, Tirado M, Teruel D, Reig R, Ràfols M
Med Clin (Barc). 1989 Mar 18;92(10):371-4.
We studied the efficacy of tazobactam (YTR 830), a new beta-lactamase inhibitor in combination with piperacillin (P) against 198 Enterobacteriaceae strains. A comparative study of susceptibility (MIC determined on Mueller Hinton agar; inoculum 10(4) cfu) was made with the combination amoxicillin (A) + clavulanic acid (CA). Of 181 strains resistant to P, 79.56% were susceptible to it in the presence of tazobactam (TZ). The characteristics of the beta-lactamases of 37 strains resistant to P + TZ (MIC greater than 40 micrograms/ml) were studied; 11 were hyperproducers of chromosomic beta-lactamase and 7 produced two types of plasmidic beta-lactamase. The MICs of TZ alone were uniform and high (64-128 micrograms/ml), independently of the characteristics of the strains beta-lactamase. Of 17 strains susceptible to P, the efficacy of P + TZ was significant among carriers of plasmidic beta-lactamase; there was practically no change in the P susceptibility among the non carriers. The efficacy of P + TZ was similar to that of A + AC against E. coli strains; it was higher against strains of Enterobacter, Citrobacter and Serratia.
我们研究了新型β-内酰胺酶抑制剂他唑巴坦（YTR 830）与哌拉西林（P）联合使用对198株肠杆菌科细菌的疗效。并与阿莫西林（A）+克拉维酸（CA）联合用药进行了药敏比较研究（在Mueller Hinton琼脂上测定MIC；接种量为10(4) cfu）。在181株对P耐药的菌株中，79.56%在有他唑巴坦（TZ）存在时对其敏感。对37株对P+TZ耐药（MIC大于40微克/毫升）菌株的β-内酰胺酶特性进行了研究；11株为染色体β-内酰胺酶高产株，7株产生两种类型的质粒β-内酰胺酶。单独使用TZ的MIC均一且较高（64 - 128微克/毫升），与菌株β-内酰胺酶的特性无关。在17株对P敏感的菌株中，P+TZ对携带质粒β-内酰胺酶的菌株疗效显著；非携带者对P的敏感性几乎没有变化。P+TZ对大肠杆菌菌株的疗效与A+AC相似；对肠杆菌属、柠檬酸杆菌属和沙雷菌属菌株的疗效更高。
